MarketCap
Facebook
X
Telegram
Kiniksa Pharmaceuticals, Ltd. Financial Ratios 2025-2011 | KNSA
Brief overview of Kiniksa Pharmaceuticals, Ltd.'s market valuation
The comparison uses the five latest available annual observations between 2021 and 2025.
The valuation comparison uses P/E 55.55x (median 55.55x), P/S 4.84x (median 4.84x), P/B 5.77x (median 3.26x). On average, multiples differ from their five-year medians by only 0%. Valuation is near its familiar historical range.
Earnings yield calculated as 1/P/E is about 1.8%, showing current profit per unit of share price.
Current measures of operating quality are ROE 10.4%, ROA 7.7%, ROCE 13.6%. Quality ratios send a mostly positive signal: resources are productive, with room for improvement.
PEG of 0.49x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
The cash conversion cycle increased 177.9 days to 196.8 days, weakening working-capital efficiency.
Overall picture
Kiniksa Pharmaceuticals, Ltd.'s multiples form a balanced picture without a clear discount or premium. Future appeal depends on earnings and return trends.
Annual Financial Ratios Kiniksa Pharmaceuticals, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
55.5 | -33.0 | 101.5 | 4.7 | -4.9 | -7.5 | -4.9 | -8.8 | - | - | - | - | - | - | - |
P/S |
4.8 | 3.4 | 5.3 | 3.9 | 20.0 | - | - | - | - | - | - | - | - | - | - |
EPS |
0.8 | -0.6 | 0.2 | 2.6 | -2.3 | -2.6 | -3.0 | -3.5 | -35.9 | - | - | - | - | - | - |
EV (Enterprise Value) |
3.31 B | 1.38 B | 1.41 B | 809 M | 695 M | 1.14 B | 782 M | 874 M | 91.5 M | 82.2 M | - | - | - | - | - |
EBITDA per Share |
1.06 | -0.61 | -0.33 | 0.18 | -2.25 | -2.51 | -3.11 | -2.18 | - | - | - | - | - | - | - |
EV/EBITDA |
-4.4 | -8.0 | -4.5 | -7.7 | - | - | - | - | - | - | - | ||||
PEG |
-0.47 | 0.49 | -1.34 | - | 27.67 | -0.11 | 0.37 | - | - | - | - | - | - | - | |
P/B |
5.8 | 3.2 | 3.3 | 2.2 | 4.2 | 3.9 | 3.5 | 3.2 | - | - | - | - | - | - | - |
P/CF |
23.8 | 55.4 | 107.5 | 149.5 | -6.1 | -8.9 | -5.0 | -10.5 | - | - | - | - | - | - | - |
ROE % |
10.40 | -9.85 | 3.21 | 46.29 | -85.35 | -51.74 | -71.81 | -36.96 | - | - | - | - | - | - | - |
ROA % |
7.73 | -7.44 | 2.68 | 39.89 | -67.84 | -46.18 | -63.59 | -32.06 | - | - | - | - | - | - | - |
ROCE % |
13.60 | -10.40 | -5.74 | 2.47 | -84.65 | -50.45 | -74.97 | -38.71 | - | - | - | - | - | - | - |
Current Ratio |
3.9 | 4.1 | 6.0 | 7.2 | 4.9 | 9.3 | 8.7 | 7.4 | - | - | - | - | - | - | - |
DSO |
15.4 | 27.2 | 22.9 | 13.8 | 18.9 | - | - | - | - | - | - | - | - | - | - |
DIO |
190.9 | 172.2 | 288.0 | 201.5 | - | - | - | - | - | - | - | - | - | - | - |
DPO |
9.6 | 30.8 | 88.2 | 77.9 | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
206.4 | 199.4 | 310.9 | 215.3 | 18.9 | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
196.8 | 168.6 | 222.7 | 137.4 | 18.9 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Kiniksa Pharmaceuticals, Ltd.
| 2026-Q1 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.3 | 0.24 | 0.12 | -0.18 | -0.06 | -0.25 | -0.2 | 0.21 | -0.18 | - | 3.23 | -0.29 | -0.36 | - | -0.44 | -0.61 | -0.72 | - | -0.66 | -0.65 | -0.48 | - | -0.49 | -0.68 | -1.27 | - | -0.51 | -1.11 | -6.45 | - | -8.25 | -6.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.39 | 0.27 | 0.19 | -0.13 | - | -0.23 | -0.15 | -0.04 | -0.15 | - | 0.67 | -0.27 | -0.33 | - | -0.42 | -0.59 | -0.72 | - | -0.63 | -0.53 | -0.52 | - | -0.55 | -0.71 | -1.3 | - | -0.54 | -1.17 | -6.59 | - | -8.36 | -6.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
6.29 | 1.67 | -6.04 | -11.32 | -4.78 | -7.03 | 55.43 | 117.20 | 100.55 | 30.17 | 15.90 | -56.72 | -61.33 | -50.18 | -64.23 | -64.01 | -58.40 | -34.53 | -46.54 | -44.49 | -48.97 | -57.70 | -66.44 | -63.18 | -53.93 | -21.72 | -3.85 | 22.76 | 42.50 | 30.36 | 30.36 | 12.49 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
4.57 | 1.12 | -4.99 | -9.28 | -3.90 | -5.95 | 46.17 | 97.76 | 83.76 | 26.89 | 14.81 | -35.07 | -49.96 | -42.87 | -55.41 | -55.88 | -51.71 | -30.83 | -41.46 | -39.54 | -43.43 | -51.10 | -58.68 | -55.63 | -47.31 | -18.84 | -52.59 | -78.76 | -96.06 | -57.34 | -57.34 | -23.59 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
9.60 | 4.74 | -3.17 | -8.76 | -7.32 | -10.16 | 5.75 | 20.54 | 8.68 | -14.56 | -28.89 | -55.30 | -59.88 | -49.73 | -63.59 | -63.12 | -56.13 | -33.49 | -47.00 | -46.65 | -53.86 | -60.94 | -70.31 | -66.17 | -56.45 | -22.93 | -4.81 | 22.67 | 43.07 | 30.81 | 30.81 | 12.70 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.8 | 4.0 | 4.2 | 4.7 | 5.0 | 5.9 | 6.2 | 6.7 | 8.4 | 7.2 | 6.1 | - | 3.6 | 4.9 | 6.5 | 6.4 | 7.7 | 9.3 | 9.3 | 9.3 | 9.3 | 8.7 | 8.7 | 8.7 | 8.7 | 7.5 | 7.5 | 7.5 | 7.5 | 2.7 | 2.7 | 2.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
11.7 | 20.9 | 21.5 | 18.4 | 15.3 | 10.9 | 18.8 | 20.5 | 18.9 | - | 5.1 | 49.8 | 47.4 | - | 21.8 | 15.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
266.2 | 172.3 | 129.6 | 144.2 | 230.1 | 227.9 | 248.7 | 280.8 | 292.0 | - | 96.2 | 120.0 | - | - | 197.7 | 158.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
73.2 | 26.8 | 26.3 | 35.7 | 48.2 | 28.6 | 8.3 | 12.1 | 60.2 | - | 9.7 | 30.7 | - | - | 95.7 | 128.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
277.9 | 193.2 | 151.1 | 162.6 | 245.4 | 238.8 | 267.6 | 301.3 | 310.9 | - | 101.3 | 169.8 | 47.4 | - | 219.4 | 173.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
204.7 | 166.4 | 124.8 | 126.9 | 197.2 | 210.1 | 259.2 | 289.2 | 250.7 | - | 91.6 | 139.1 | 47.4 | - | 123.7 | 45.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Kiniksa Pharmaceuticals, Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
